题目：蛋白质药物研究进展

报告人：刘玲  博士

Biotechnology Discovery Research Eli Lilly and Company

Lilly Corporation Center, Indianapolis

时间：6月3日（周二）下午4:00

地点：东十一楼二楼会议室

报告人简介：

Research Advisor at Biotechnology Discovery Research at Eli Lilly and Company, received her doctorate in molecular biology from the University of Western Ontario in 1992.  After completing postdoctoral studies at the British Columbia Cancer Research Center in Vancouver, Dr. Liu joined Lilly in 1997 as a senior biologist and was promoted to senior research scientist, principal research scientist and research advisor.  Dr. Liu is recognized for her leadership and technical contributions to several programs targeting cancer and inflammatory diseases.  As the lead biologist or the team leader on numerous protein and antibody projects, she has been responsible for validating the targets, developing assays for potential therapeutic antibodies and proteins, working across functional areas to generate the data that influenced strategy and supported milestone achievements, leading team effort that successfully developed a therapeutic candidate antibody which has entered clinical development.  Her work has advanced one molecule from concept to clinical development and multiple molecules at different stage of preclinical development.  Moreover, Dr. Liu has been instrumental in developing and implementing several new solutions critical for biotechnology efforts.   In addition to numerous pending patents, external presentations and publications, she has been awarded three patents.